Alkermes Moves Beyond Reformulations As It Preps Three New Compounds For Clinic
This article was originally published in The Pink Sheet Daily
Alkermes multi-year efforts to move up from its successful reformulations for partners takes a step forward as the biotech presents its expanding clinical pipeline to investors, highlighting early-stage compounds for multiple sclerosis, pain, and cancer.
You may also be interested in...
FDA approved the oral multiple sclerosis drug March 27 to treat patients with relapsing forms of the disease. Labeling includes data from one trial that showed patients on Tecfidera experienced disability progression less often.
Otsuka and Lundbeck’s newly approved long-acting antipsychotic Abilify Maintena enters a sub-sector of the anti-psychotic market dominated by Johnson & Johnson for the last decade, but the new competitor may be able to gain ground by helping to grow the patient population.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.